The Wound Healing Platform Generates a First Commercial Partnership For Advitech
06 December 2007
Following the October 10, 2007 announcement made by Advitech ('Advitech' or the 'Corporation') on positive pre-clinical results for wound healing applications, the Corporation announces today the signature of a letter of intent with Dectro International for the sale and marketing of a complete microdermabrasion product line. A definitive agreement must be finalized by December 31, 2007.
The IM product line, which will comprise specific dairy bioactives, generated from the XP-828L technological platform, will be a unique approach combining systemic and topical products aiming for an accelerated recovery process following a microdermabrasion procedure. The product line is a result of the Corporation's ongoing work on both a new platform in development, and its main technological platform, XP-828L. The line will include three products: IMO-137 (oral) will be used throughout a preparation phase and after treatment, IMS-137 (topical serum) will be used immediately after the procedure and IMC-137 (cream) will be used at home by the customer to assist in the healing process.
"We are proud of this upcoming partnership with Dectro since that will allow us to commercialize a line of unique products in 2008. We have made exceptional progress, in the past few months, with this new application and expect to rapidly generate additional revenue. Dectro is a world leader in microdermabrasion and together we hope to build a strong portfolio of products around Dectro's Gala brand name” commented Renaud Beauchesne, Advitech's President and Chief Executive Officer. "The association Advitech-Dectro will enable us to offer a unique concept of products and solidify our leadership position," added Mr Clément Beaumont, President and General Manager of Dectro International.
The IM product line will be included in the Gala cosmetics line developed and sold exclusively by Dectro in estheticians clinics.
